A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with newly Diagnosed Diffuse Large B-cell Lymphoma
Newly Diagnosed Diffuse Large B-cell Lymphoma
DRUG: Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone
Overall Response Rate (ORR), Overall Response Rate, two years|Progression Free Survival (PFS), Progression Free Survival, two years
Overall Survival (OS), Overall Survival, two years|Disease free survival（DFS）, Disease free survival, two years
This study adopts an open, single arm, prospective clinical collaborative research approach. And the aim is to observe the efficacy and safety of the combination therapy of Obutinib or Desitabine with Rituximab and Cyclophosphamide in elderly patients with newly diagnosed diffuse large B-cell lymphoma.